Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Sep;30(3):343–349. doi: 10.1128/aac.30.3.343

In vitro and pharmacokinetic properties of the carbapenems.

R Wise
PMCID: PMC180556  PMID: 3535659

Full text

PDF
345

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Basker M. J., Boon R. J., Box S. J., Prestige E. A., Smith G. M., Spear S. R. Properties of MM 13902 and other carbapenem antibiotics in vitro and in vivo. J Antibiot (Tokyo) 1983 Apr;36(4):416–422. doi: 10.7164/antibiotics.36.416. [DOI] [PubMed] [Google Scholar]
  2. Basker M. J., Boon R. J., Hunter P. A. Comparative antibacterial properties in vitro of seven olivanic acid derivatives: MM 4550, MM 13902, MM 17880, MM 22380, MM 22381, MM 22382 and MM 22383. J Antibiot (Tokyo) 1980 Aug;33(8):878–884. doi: 10.7164/antibiotics.33.878. [DOI] [PubMed] [Google Scholar]
  3. Basker M. J. The carbapenem family. J Antimicrob Chemother. 1982 Jul;10(1):4–7. doi: 10.1093/jac/10.1.4. [DOI] [PubMed] [Google Scholar]
  4. Brown A. G., Butterworth D., Cole M., Hanscomb G., Hood J. D., Reading C., Rolinson G. N. Naturally-occurring beta-lactamase inhibitors with antibacterial activity. J Antibiot (Tokyo) 1976 Jun;29(6):668–669. doi: 10.7164/antibiotics.29.668. [DOI] [PubMed] [Google Scholar]
  5. Drusano G. L., Standiford H. C., Bustamante C., Forrest A., Rivera G., Leslie J., Tatem B., Delaportas D., MacGregor R. R., Schimpff S. C. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother. 1984 Nov;26(5):715–721. doi: 10.1128/aac.26.5.715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hood J. D., Box S. J., Verrall M. S. Olivanic acids, a family of beta-lactam antibiotics with beta-lactamase inhibitory properties produced by Streptomyces species. II. Isolation and characterisation of the olivanic acids MM 4550, MM 13902 and MM 17880 from Streptomyces olivaceus. J Antibiot (Tokyo) 1979 Apr;32(4):295–304. doi: 10.7164/antibiotics.32.295. [DOI] [PubMed] [Google Scholar]
  7. Ito T., Ezaki N., Ohba K., Amano S., Kondo Y., Miyado H. S., Shomura T., Sezaki M., Niwa T., Kojima M. A novel beta-lactamase inhibitor, SF-2103 A produced by a Streptomyces. J Antibiot (Tokyo) 1982 Apr;35(4):533–535. doi: 10.7164/antibiotics.35.533. [DOI] [PubMed] [Google Scholar]
  8. Kahan F. M., Kropp H., Sundelof J. G., Birnbaum J. Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother. 1983 Dec;12 (Suppl 500):1–35. doi: 10.1093/jac/12.suppl_d.1. [DOI] [PubMed] [Google Scholar]
  9. Kahan J. S., Kahan F. M., Goegelman R., Currie S. A., Jackson M., Stapley E. O., Miller T. W., Miller A. K., Hendlin D., Mochales S. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot (Tokyo) 1979 Jan;32(1):1–12. doi: 10.7164/antibiotics.32.1. [DOI] [PubMed] [Google Scholar]
  10. Kropp H., Gerckens L., Sundelof J. G., Kahan F. M. Antibacterial activity of imipenem: the first thienamycin antibiotic. Rev Infect Dis. 1985 Jul-Aug;7 (Suppl 3):S389–S410. doi: 10.1093/clinids/7.supplement_3.s389. [DOI] [PubMed] [Google Scholar]
  11. Kropp H., Sundelof J. G., Hajdu R., Kahan F. M. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother. 1982 Jul;22(1):62–70. doi: 10.1128/aac.22.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kropp H., Sundelof J. G., Kahan J. S., Kahan F. M., Birnbaum J. MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob Agents Chemother. 1980 Jun;17(6):993–1000. doi: 10.1128/aac.17.6.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Leanza W. J., Wildonger K. J., Miller T. W., Christensen B. G. N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics. J Med Chem. 1979 Dec;22(12):1435–1436. doi: 10.1021/jm00198a001. [DOI] [PubMed] [Google Scholar]
  14. Nakayama M., Iwasaki A., Kimura S., Mizoguchi T., Tanabe S., Murakami A., Watanabe I., Okuchi M., Itoh H., Saino Y. Carpetimycins A and B, new beta-lactam antibiotics. J Antibiot (Tokyo) 1980 Nov;33(11):1388–1390. doi: 10.7164/antibiotics.33.1388. [DOI] [PubMed] [Google Scholar]
  15. Norrby S. R., Alestig K., Björnegård B., Burman L. A., Ferber F., Huber J. L., Jones K. H., Kahan F. M., Kahan J. S., Kropp H. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother. 1983 Feb;23(2):300–307. doi: 10.1128/aac.23.2.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Norrby S. R., Alestig K., Ferber F., Huber J. L., Jones K. H., Kahan F. M., Meisinger M. A., Rogers J. D. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrob Agents Chemother. 1983 Feb;23(2):293–299. doi: 10.1128/aac.23.2.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Norrby S. R., Rogers J. D., Ferber F., Jones K. H., Zacchei A. G., Weidner L. L., Demetriades J. L., Gravallese D. A., Hsieh J. Y. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):707–714. doi: 10.1128/aac.26.5.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Okamura K., Hirata S., Okumura Y., Fukagawa Y., Shimauchi Y., Kouno K., Ishikura T. PS-5, a new beta-lactam antibiotic from Streptomyces. J Antibiot (Tokyo) 1978 May;31(5):480–482. doi: 10.7164/antibiotics.31.480. [DOI] [PubMed] [Google Scholar]
  19. Parker W. L., Rathnum M. L., Wells J. S., Jr, Trejo W. H., Principe P. A., Sykes R. B. SQ 27,860, a simple carbapenem produced by species of Serratia and Erwinia. J Antibiot (Tokyo) 1982 Jun;35(6):653–660. doi: 10.7164/antibiotics.35.653. [DOI] [PubMed] [Google Scholar]
  20. Richmond M. H., Sykes R. B. The beta-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol. 1973;9:31–88. doi: 10.1016/s0065-2911(08)60376-8. [DOI] [PubMed] [Google Scholar]
  21. Shannon K., King A., Phillips I. Beta-lactamases with high activity against imipenem and Sch 34343 from Aeromonas hydrophila. J Antimicrob Chemother. 1986 Jan;17(1):45–50. doi: 10.1093/jac/17.1.45. [DOI] [PubMed] [Google Scholar]
  22. Shibamoto N., Koki A., Nishino M., Nakamura K., Kiyoshima K., Okamura K., Okabe M., Okamoto R., Fukagawa Y., Shimauchi Y. PS-6 and PS-7, new beta-lactam antibiotics. Isolation, physicochemical properties and structures. J Antibiot (Tokyo) 1980 Oct;33(10):1128–1137. doi: 10.7164/antibiotics.33.1128. [DOI] [PubMed] [Google Scholar]
  23. Shibamoto N., Nishino M., Okamura K., Fukagawa Y., Ishikura T. PS-8, a minor carbapenem antibiotic. J Antibiot (Tokyo) 1982 Jun;35(6):763–765. doi: 10.7164/antibiotics.35.763. [DOI] [PubMed] [Google Scholar]
  24. Tally F. P., Jacobus N. V., Gorbach S. L. In vitro activity of thienamycin. Antimicrob Agents Chemother. 1978 Sep;14(3):436–438. doi: 10.1128/aac.14.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tanaka K., Shoji J., Terui Y., Tsuji N., Kondo E., Mayama M., Kawamura Y., Hattori T., Matsumoto K., Yoshida T. Asparenomycin A, a new carbapenem antibiotic. J Antibiot (Tokyo) 1981 Jul;34(7):909–911. doi: 10.7164/antibiotics.34.909. [DOI] [PubMed] [Google Scholar]
  26. Tanaka K., Shoji J., Terui Y., Tsuji N., Kondo E., Mayama M., Kawamura Y., Hattori T., Matsumoto K., Yoshida T. Asparenomycin A, a new carbapenem antibiotic. J Antibiot (Tokyo) 1981 Jul;34(7):909–911. doi: 10.7164/antibiotics.34.909. [DOI] [PubMed] [Google Scholar]
  27. Tausk F., Evans M. E., Patterson L. S., Federspiel C. F., Stratton C. W. Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1985 Jul;28(1):41–45. doi: 10.1128/aac.28.1.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tsuji N., Nagashima K., Kobayashi M., Terui Y., Matsumoto K., Kondo E. The structures of pluracidomycins, new carbapenem antibiotics. J Antibiot (Tokyo) 1982 Apr;35(4):536–540. doi: 10.7164/antibiotics.35.536. [DOI] [PubMed] [Google Scholar]
  29. Vu H., Nikaido H. Role of beta-lactam hydrolysis in the mechanism of resistance of a beta-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta-lactams. Antimicrob Agents Chemother. 1985 Mar;27(3):393–398. doi: 10.1128/aac.27.3.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wang C., Calandra G. B., Aziz M. A., Brown K. R. Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience. Rev Infect Dis. 1985 Jul-Aug;7 (Suppl 3):S528–S536. doi: 10.1093/clinids/7.supplement_3.s528. [DOI] [PubMed] [Google Scholar]
  31. Wise R., Andrews J. M., Patel N. N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother. 1981 May;7(5):521–529. doi: 10.1093/jac/7.5.521. [DOI] [PubMed] [Google Scholar]
  32. Yamaguchi A., Hirata T., Sawai T. Novel carbapenem derivative SF2103A: studies on the mode of beta-lactamase inactivation. Antimicrob Agents Chemother. 1984 Mar;25(3):348–353. doi: 10.1128/aac.25.3.348. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES